Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002284 · ClinicalTrials.gov registry record · NA

A Study of Azidothymidine (AZT) in the Treatment of HIV Infection in Patients Receiving a Bone Marrow Transplant

A NA study of HIV Infections and Lymphoma, Non-Hodgkin, sponsored by Glaxo Wellcome.

Completed
Registry status
NA
Development phase
1
Study location

NCT00002284: Completed NA study of HIV Infections and Lymphoma, Non-Hodgkin, sponsored by Glaxo Wellcome.

NCT00002284 is a NA study of HIV Infections and Lymphoma, Non-Hodgkin that has completed, run by Glaxo Wellcome. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002284, a NA study of HIV Infections and Lymphoma, Non-Hodgkin, has completed, sponsored by Glaxo Wellcome.

COMPLETED
Registry status
NA
Development phase
1
Study location

Study Summary

To determine whether zidovudine (AZT) in conjunction with bone marrow transplantation prevents the reinfection of donor hematopoietic/lymphoid cells in patients with positive HTLV III antibody and large cell/diffuse histiocytic lymphoma. Patients who are candidates will be evaluated for HTLV III activity and drug levels.

Conditions Studied

HIV Infections Lymphoma, Non-Hodgkin

Interventions

  • DRUG Zidovudine

Study Locations (1)

Maryland

  • Johns Hopkins Hemapheresis Treatment Ctr - Baltimore

Trial Details

FieldValue
Phase NA
Glaxo Wellcome

65 total trials

What the finished NCT00002284 record still lists

NCT00002284 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Zidovudine is the first listed.

NCT00002284 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT00002284 about?

NCT00002284 is a clinical study titled "A Study of Azidothymidine (AZT) in the Treatment of HIV Infection in Patients Receiving a Bone Marrow Transplant". To determine whether zidovudine (AZT) in conjunction with bone marrow transplantation prevents the reinfection of donor hematopoietic/lymphoid cells in patients with positive HTLV III antibody and large cell/diffuse histiocytic lymphoma. Patients who are candidates will be evaluated for HTLV III act...

What is the current status of trial NCT00002284?

This trial is currently completed. It is a NA study.

What conditions does trial NCT00002284 study?

This clinical trial studies the following conditions: HIV Infections, Lymphoma, Non-Hodgkin.

What interventions are being tested in trial NCT00002284?

The interventions under investigation include: Zidovudine (DRUG).

Who is sponsoring clinical trial NCT00002284?

This trial is sponsored by Glaxo Wellcome, which has 65 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002284 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Related registry views

Source: ClinicalTrials.gov NCT00002284, the US trial registry maintained by the National Library of Medicine. NCT00002284 (unsized enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.